Status:
COMPLETED
Neurobiology and Treatment of Reading Disability in NF-1
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Neurofibromatosis Type 1
Reading Disabilities
Eligibility:
All Genders
8-17 years
Phase:
NA
Brief Summary
The goal of this trial is to determine if children with neurofibromatosis type 1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment pro...
Detailed Description
The most common concern of parents of children with neurofibromatosis type 1 (NF-1) is learning disabilities (LD). Approximately one half of all children with NF-1 have LD-the most debilitating and co...
Eligibility Criteria
Inclusion
- This study will be open to all individuals, ages 8 to 17 years, who meet eligibility criteria regardless of race, gender, or socioeconomic status.
- The Reading Disabilities group (including those with NF-1) is defined by scoring equal to or less than the 25th percentile on measures of basic word reading skills.
- The Control group (including those with NF1) is defined by scoring equal to or above the 40th percentile on the average of the Letter Word Identification and Word Attack subtests from the WJ-III.
Exclusion
- Any child, regardless of which group he/she is recruited for, will be excluded if he/she meets any of the following criteria (determined during phone screening, medical review, and during testing):
- is in foster care;
- previous diagnosis of mental retardation;
- known uncorrectable visual impairment;
- history of known neurological disorder (e.g., epilepsy, spina bifida, cerebral palsy, traumatic brain injury);
- documented hearing impairment greater than 25 dB loss in either ear;
- medical contraindication to MRI procedures, if participating in MRI (including exposure to metal and pregnancy);
- individuals known to have an IQ below 70;
- history or presence of a pervasive developmental disorder;
- during the DICA-IV parents indicate the presence of any severe psychiatric diagnoses or pervasive developmental disorder.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00624234
Start Date
February 1 2006
End Date
January 1 2017
Last Update
July 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University, Vanderbilt University Institute of Imaging Science
Nashville, Tennessee, United States, 37232-2310